Earlier strategies focused on autologous DCs loaded with antigens shared among patients, such as MUC1 [39], p53 peptide [46], Her2/neu, hTERT, and PADRE peptides [47], WT-1 [48], the antigen folate receptor alpha [49], and the use of autologous DCs loaded with antigens from allogeneic ovarian cancer cell lines [50]. This evidence concerns the gene ERBB2 and ovarian cancer.